JPRN-jRCT2031210616已完成1 期
A Clinical Pharmacological Study of MT-3921 in Subjects with Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM)
Kazuoki Kondou0 个研究点目标入组 15 人开始时间: 2022年2月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Additional screening criteria check may apply for qualification:
- •- Subjects aged 20 years or older on the day of consent
- •- Subjects with a confirmed diagnosis of HAM according to the diagnostic algorithm of Practical Guideline for HAM 2019 on the day of consent
- •- Subjects with an Osame's motor disability score (OMDS) of >=4 and =<6 at Screening and on the first day of the Treatment period (predose)
- •- Subjects with no change in OMDS for at least 3 months before the day of consent
- •- Subjects with a CSF concentration neopterin of >=6 pmol/mL at Screening
- •-Subjects on maintenance oral steroid therapy who have continued to receive the same dose equivalent to =<10 mg/day of prednisolone for at least 3 months before the day of consent
排除标准
- •Additional screening criteria check may apply for qualification:
- •- Subjects who have a history of anaphylaxis or clinically significant allergic reactions due to administration of antibody products
- •- Subjects exhibiting or with a history of malignant tumor.
- •- Subjects with adult T-cell leukemia/lymphoma (ATL) or those with positive HTLV-1 clonality test (Southern blot) at screening and suspected of having ATL
- •- Subjects with spinal cord compression lesions, such as cervical spine disease, disc herniation, and ossification of the yellow ligament
- •- Subjects with psychiatric disorders, epileptic seizures, or dementia.
- •- Subjects with suicide attempts or suicidal ideation corresponding to item 4 or 5 on the Columbia Suicide Rating Scale (C-SSRS) at screening and/or on the first day of the Treatment period (predose)
- •- Subjects exhibiting or with a history of hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection.
- •- Subjects with the novel Coronavirus disease 2019 (COVID-19)
- •- Subjects with severe illness
- •- Male or female subjects of childbearing potential who do not agree to use a contraceptive measure from the day of consent to 16 weeks after the last dose of the investigational medical product
- •- Female subjects who are pregnant, lactating, or may be pregnant
- •- Subjects who have received anti-repulsive guidance molecule (RGM) a antibody containing this investigational medical product
- •- Subjects who participated in other clinical studies (including clinical trials) and received drugs (including investigational medical products) or therapy within 12 weeks before the day of consent
研究者
相似试验
已完成
1 期
A Clinical Pharmacology Study of MT-3921 in Healthy Adult MalesAcute Traumatic Cervical Spinal Cord Injury, HTLV-1-Associated Myelopathy (HAM)JPRN-jRCT2031220182Kondo Kazuoki10
已完成
1 期
A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)HTLV-1-Associated Myelopathy (HAM)NCT05240612Mitsubishi Tanabe Pharma Corporation15
已完成
1 期
A Clinical Pharmacology Study of MT-3921 in Healthy Adult MalesHealthy Adult MalesNCT05396235Mitsubishi Tanabe Pharma Corporation10
已完成
1 期
Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord InjurySpinal Cord InjuryNCT04096950Mitsubishi Tanabe Pharma America Inc.3
进行中（未招募）
1 期
A study of MT-3724 investigational drug for the treatment of patients with resistant or recurring B-cell cancerrelapsed or refractory diffuse large B-cell lymphoma (DLBCL)MedDRA version: 21.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001073-86-ESMolecular Templates, Inc.100